VLA-4 antagonists

Drugs of the Future

Volumn 26, Issue 10, 2001, Pages 985-998

  Tilley, J W ^a   Sidduri, A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DICHLOROBENZYL ETHER; 3 FLUOROPROLINOL; AZACYCLOBUTYL BIPHENYLALANINE; BENZOXAZOLE DERIVATIVE; BETA1 INTEGRIN; BIO 1211; BIO 1272; CARBANILAMIDE; CARBONYL DERIVATIVE; CT 5219; CT 757; CT 767; CY 9607; CY 9701; CYCLOPEPTIDE; HYDANTOIN DERIVATIVE; IVL 745; N BENZYLPYROGLUTAMYL DERIVATIVE; NATALIZUMAB; PHENOXYACYLLEUCYLPHENYLALANINE DERIVATIVE; PHENYLSULFONYL BIPHENYLALANINE; PROBUCOL SUCCINATE; PROTEIN INHIBITOR; SB 683698; SQUARIC ACID DERIVATIVE; TBC 3342; TBC 3486; TR 14035; TR 9109; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; ZD 7349;

ASTHMA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG STRUCTURE; ENTERITIS; FATIGUE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 0035655590     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.10.858716     Document Type: Review

References (115)

1. 7, on human leukocytes
2. 1
3. Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin
4. 7 under different activity states
5. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 Å resolution
6. The crystal structure of an N-terminal two domain fragment of vascular cell adhesion molecule 1 (VCAM-1): A cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1 α-4 integrin interaction
7. Competitive binding of vascular cell adhesion molecule-1 and the HepIVIIIC S domain of fibronectin to the integrin α-4 β-1
8. The minimal essential sequence for a major cell type-specific adhesion site (CS-1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine
9. 1
10. 1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin
11. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue
12. 4 integrins modifies integrin-dependent biological responses
13. Integrin affinity modulation
14. Road signs guiding leukocytes along the inflammation superhighway
15. Integrins: Emerging paradigms of signal transduction
16. Association of the membrane proximal regions of the α and β subunit cytoplasmic domains constrains an integrin in the inactive state
17. Folding of the N-terminal, ligand-binding region of integrin α-subunits into β-propeller domain
18. Multiple loop structures critical for ligand binding of the integrin α-4 subunit in the upper face of the β-propeller mode 1
19. From crystal clear ligand binding to designer 1 domains
20. Integrin cell adhesion receptors and the concept of agonism
21. CD49d expression and function on allergen-stimulated T cells from blood and airway
22. The increased number of very late activation-4 positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients
23. T-cell function and migration
24. 4 integrins mediate lymphocyte attachment and rolling under physiologic flow
25. 4-integrin supports leukocyte rolling and adhesion in chronically inflamed postcapillary venules in vivo
26. Adhesion receptors
27. In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with airflow limitation: In vivo evidence of VCAM-VLA-4 interaction in selective eosinophil infiltration
28. VCAM-1 levels after segmental challenge correlate with eosinophil influx and IL-4 and IL-5 production, and the late phase response
29. Blockade of CD49d inhibits allergic airway pathologies independent of effects on leukocyte recruitment
30. 4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma
31. Role of very late activation antigen-4 in the lungs and airway lumen of sensitized Brown Norway rats
32. A monoclonal antibody against very late activation antigen-4 inhibits eosinophil accumulation and late asthmatic response in a guinea pig model of asthma
33. Blockade of late-phase airway response and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4
34. 1 that inhibit allergic airway responses
35. Direct vascular targets for atherosclerosis prevention
36. Vascular adhesion molecule-1 (VCAM-1), an inflammatory gene target for new therapeutics
37. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
38. Blocking of very late antigen-4 intergrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet
39. The role of integrins in immune-mediated diseases of the nervous system
40. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis
41. 7 integrins contribute to demyelinating disease of the central nervous system
42. 4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment
43. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD 106) expressed on fibroblast-like synoviocytes
44. Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4
45. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis
46. Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats
47. New insights into the immunopathology of human inflammatory bowel disease
48. Adhesion molecules in inflammatory bowel disease
49. 7
50. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1
51. Monoclonal antibodies specific for P7 integrin and mucosal addressin cell adhesion molecule-1 (MADCAM- 1) reduce inflammation in the colon of scid mice reconstituted with CD45RB high CD4+ T cells
52. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice
53. Emigrated neutrophils regulate vertricular contractillity via α-4 integrin
54. α-4 integrin mediates neutrophil-induced free radical injury to cardiac myocytes
55. Inhibition of α-4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats
56. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen
57. Adhesion receptors on haematopoietic progenitor cells
58. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells
59. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α-4 β-1 integrin enhances production of osteoclast-stimulating activity
60. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
61. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice
62. Targeted disruption of the murine VCAM 1 gene: Essential role of VCAM-1 in chorioallantoic fusion and placentation
63. Conditional vasucular cell adhesion molecule 1 deletion in mice: Impaired lymphocyte migration to bone marrow
64. Neonatally induced inactivation of the vascular cell adhesion molecule-1 gene impairs B cell localization and T cell-dependent humoral immune response
65. Natalizumab Elan
66. A placebo-controlled, pharmacodynamic, pharmacokinetic, tolerability and safety study of three doses of intravenous natalizumab in multiple sclerosis
67. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
68. The effect of anti-α-4 integrin antibody on brain lesion activity in MS
69. A randomized double-blind, placebo-controlled, pan-European study of a recombinant humanized antibody to α-4 integrin (Antegren®) in moderately to severe active Crohn's disease
70. ®)
71. A novel cyclic pentapeptide inhibits α-4/β-1 and α-5/β-1 integrin-mediated cell adhesion
72. Potent α-4 β-1 peptide antagonists as potential anti-inflammatory agents
73. The design and synthesis of potent cyclic peptide VCAM/VLA-4 antagonists incorporating an achiral Asp-Pro mimetic
74. Cyclic thioether peptide mimetics as VCAM-VLA-4 antagonists
75. 1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-LeuAsp-Val-dArg-dArg) (ZD7349) compatible with depot formulation
76. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (α-4 β-1 integrin)-mediated cell adhesion based on the lle-Leu-Asp-Val tetrapeptide
77. Small molecule inhibitors of the leukocyte integrin VLA-4
78. CY-9701, a small molecule VLA-4 inhibitor modulates proinflammatory cytokines in an allergic mouse asthma model
79. SAR studies of the leucine portion of Bio-1050, a potent and selective nanomolar antagonist of the integrin VLA-4 (α-4 β-1)
80. Multiple activation states of integrin α-4 β-1 detected through their different affinities for a small molecule ligand
81. IVL-745, a potent, selective, low molecular weight antagonist of VLA-4 mediated cell adhesion
82. The VLA-4 agtagonist IVL-745 is a novel and potent inhibitor of human lymphocyte adhesion to VCAM1
83. The VLA-4 antagonist, IVL-745 is a novel and potent inhibitor of eosinophil adhesion to VCAM
84. The VLA-4 antagonist IVL-745 is a novel and potent inhibitor of VCAM-1 co-stimulated human T-cell activation
85. In vivo profile of the novel VLA-4 antagonist IVL-745 in antigen induced airway inflammation in the rat
86. TBC3486: Novel highly potent, and selective VLA-4 antagonist
87. Novel N,N-disubstituted amides that are highly potent VLA-4 antagonists
88. Novel urea derivatives that are potent VLA-4 antagonists
89. 1 integrin antagonists
90. From cyclic peptide to small molecule antagonists of VLA-4
91. Development of CT757: A potent and highly selective small molecule inhibitor of VLA-4
92. Acylated p-amino-L-phenylalanines with VLA-4/VCAM-1 inhibitory activity
93. VLA-4/VCAM inhibitors - Dipeptide p-amino-L-phenylalanine amides
94. 1 integrin mediated cell adhesion
95. N-Benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists
96. Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists
97. Discovery of TR-14035; an orally active dual α-4-β-1 integrin antagonist
98. The discovery of sulfonated dipeptides as potent VLA-4 antagonists